GO
Loading...

Bristol-Myers Squibb Co

More

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Final Glance: Pharmaceuticals companies Thursday, 28 Aug 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 43 or. 6 percent, to $74.91. Bristol-Myers Squibb Co. rose$. 29 or. 6 percent, to $50.54. Hospira fell$. 02 or percent, to $54.22.

  • Midday Glance: Pharmaceuticals companies Thursday, 28 Aug 2014 | 1:19 PM ET

    Baxter International Inc. fell$. 38 or. 5 percent, to $74.96. Bristol-Myers Squibb Co. rose$. 39 or. 8 percent, to $50.64. Hospira rose$. 01 or percent, to $54.25.

  • Early Glance: Pharmaceuticals companies Thursday, 28 Aug 2014 | 10:31 AM ET

    Baxter International Inc. fell$. 47 or. 6 percent, to $74.87. Bristol-Myers Squibb Co. rose$. 24 or. 5 percent, to $50.49. Hospira fell$. 14 or. 3 percent, to $54.10.

  • Final Glance: Pharmaceuticals companies Wednesday, 27 Aug 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 19 or. 3 percent, to $75.34. Bristol-Myers Squibb Co. fell$. 52 or 1.0 percent, to $50.25. Hospira rose$. 20 or. 4 percent, to $54.24.

  • Early Glance: Pharmaceuticals companies Wednesday, 27 Aug 2014 | 10:18 AM ET

    Baxter International Inc. fell$. 50 or. 7 percent, to $75.03. Bristol-Myers Squibb Co. fell$. 50 or 1.0 percent, to $50.27. Hospira rose$. 04 or. 1 percent, to $54.08.

  • Final Glance: Pharmaceuticals companies Tuesday, 26 Aug 2014 | 6:05 PM ET

    Baxter International Inc. rose$. 13 or. 2 percent, to $75.53. Bristol-Myers Squibb Co. rose$. 04 or. 1 percent, to $50.77. Hospira fell$. 56 or 1.0 percent, to $54.04.

  • Midday Glance: Pharmaceuticals companies Tuesday, 26 Aug 2014 | 1:31 PM ET

    Baxter International Inc. rose$. 12 or. 2 percent, to $75.52. Bristol-Myers Squibb Co. fell$. 02 or percent, to $50.71. Hospira fell$. 22 or. 4 percent, to $54.38.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Early Glance: Pharmaceuticals companies Tuesday, 26 Aug 2014 | 11:12 AM ET

    Baxter International Inc. rose$. 06 or. 1 percent, to $75.46. Bristol-Myers Squibb Co. rose$. 12 or. 2 percent, to $50.85. Johnson& Johnson rose$. 06 or. 1 percent, to $103.29.

  • Final Glance: Pharmaceuticals companies Monday, 25 Aug 2014 | 6:24 PM ET

    Baxter International Inc. rose$. 36 or. 5 percent, to $75.40. Bristol-Myers Squibb Co. rose$. 55 or 1.1 percent, to $50.73. Johnson& Johnson rose$. 13 or. 1 percent, to $103.23.

  • Early Glance: Pharmaceuticals companies Monday, 25 Aug 2014 | 10:37 AM ET

    Baxter International Inc. rose$. 45 or. 6 percent, to $75.49. Bristol-Myers Squibb Co. rose$. 34 or. 7 percent, to $50.52. Hospira rose$. 28 or. 5 percent, to $54.88.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Final Glance: Pharmaceuticals companies Friday, 22 Aug 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 76 or 1.0 percent, to $75.04. Bristol-Myers Squibb Co. rose$. 19 or. 4 percent, to $50.18. Hospira fell$. 14 or. 3 percent, to $54.60.

  • Midday Glance: Pharmaceuticals companies Friday, 22 Aug 2014 | 1:22 PM ET

    Baxter International Inc. fell$. 57 or. 8 percent, to $75.23. Bristol-Myers Squibb Co. rose$. 16 or. 3 percent, to $50.15. Hospira fell$. 13 or. 2 percent, to $54.61.

  • Final Glance: Pharmaceuticals companies Thursday, 21 Aug 2014 | 6:08 PM ET

    Baxter International Inc. rose$. 55 or. 7 percent, to $75.80. Bristol-Myers Squibb Co. fell$. 05 or. 1 percent, to $49.99. Hospira fell$. 17 or. 3 percent, to $54.74.

  • FDA clears Eliquis for new use against blood clots Thursday, 21 Aug 2014 | 3:10 PM ET

    WASHINGTON— Bristol-Myers Squibb and Pfizer said Thursday that federal regulators have expanded approval of their blood thinner Eliquis to treat two types of dangerous blood clots. The Food and Drug Administration cleared the drug for patients suffering from or at risk of deep vein thrombosis and pulmonary embolism.

  • Midday Glance: Pharmaceuticals companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 71 or. 9 percent, to $75.96. Bristol-Myers Squibb Co. fell$. 13 or. 2 percent, to $49.92. Hospira fell$. 12 or. 2 percent, to $54.79.

  • Final Glance: Pharmaceuticals companies Wednesday, 20 Aug 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 12 or. 2 percent, to $75.25. Bristol-Myers Squibb Co. fell$. 26 or. 5 percent, to $50.04. Hospira rose$. 99 or 1.8 percent, to $54.91.

  • Midday Glance: Pharmaceuticals companies Wednesday, 20 Aug 2014 | 1:49 PM ET

    Baxter International Inc. rose$. 11 or. 1 percent, to $75.24. Bristol-Myers Squibb Co. fell$. 18 or. 4 percent, to $50.12. Hospira rose$. 70 or 1.3 percent, to $54.62.